Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M558Revenue $M0Net Margin (%)-9,063.3Z-Score17.3
Enterprise Value $M492EPS $0Operating Margin %-8,601.5F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-9,063.3Higher ROA y-yN
Price/Book8.510-y EBITDA Growth Rate %0Quick Ratio24.3Cash flow > EarningsN
Price/Sales6545-y EBITDA Growth Rate %0Current Ratio24.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-85.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M21.3ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with OCUL

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

OCUL is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


OCUL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SVLSF IV, LLC10% Owner 2014-07-30Buy715,380$13102.69view
Sawhney AmarpreetPresident and CEO, 10% Owner 2014-07-30Buy76,922$13102.69view
CHV II, L.P.10% Owner 2014-07-30Buy153,846$13102.69view

Press Releases about OCUL :

    Quarterly/Annual Reports about OCUL:

    News about OCUL:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 

    More From Other Websites
    3 Biotech Stocks With Upcoming Data That Could Be Huge Jan 22 2015
    Ocular Therapeutix™ Enrolls First Patient in Phase 2 Clinical Trial for Sustained Release... Jan 21 2015
    Ocular Therapeutix™ Enrolls First Patient in Phase 2 Clinical Trial for Sustained Release... Jan 21 2015
    Ocular Therapeutix™ to Present at Oppenheimer 25th Annual Healthcare Conference Dec 02 2014
    Ocular Therapeutix™ to Present at Oppenheimer 25th Annual Healthcare Conference Dec 02 2014
    Will Ocular Therapeutix (OCUL) Continue to Surge Higher? Nov 26 2014
    IPO Stock Watch: Second Sight Medical Sees Strong IPO Nov 19 2014
    Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results Nov 12 2014
    Ocular Therapeutix Inc Earnings Call scheduled for 8:00 am ET today Nov 12 2014
    OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 12 2014
    Q3 2014 Ocular Therapeutix Inc Earnings Release - 07:00 am ET Nov 12 2014
    Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results Nov 12 2014
    Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial... Nov 12 2014
    Ocular Therapeutix™ Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release... Nov 12 2014
    Ocular Therapeutix™ Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release... Nov 12 2014
    Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial... Nov 12 2014
    Ocular Therapeutix™ to Report Third Quarter 2014 Financial Results and Provide Business Updates on... Nov 05 2014
    Ocular Therapeutix™ to Report Third Quarter 2014 Financial Results and Provide Business Updates on... Nov 05 2014
    Ocular Therapeutix™ to Participate in Two Investor Conferences in November 2014 Oct 31 2014
    Ocular Therapeutix™ to Participate in Two Investor Conferences in November 2014 Oct 31 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK